Marc Robillard
Chief Scientific Officer Tagworks Pharmaceuticals
Marc is co-founder and CSO of Tagworks, a pioneer of in vivo click chemistry, and the inventor of the now widely used Click-to-Release approach for improved systemic therapies. He spun the technology out of Philips and then drove its development into a broadly applicable platform technology for systemic therapies, while building a broad IP estate, productive partnerships, and a strong investor base. Before spinning out, Marc worked at Philips Healthcare on molecular imaging and drug delivery programs, eventually focusing on in vivo click chemistry applications in these domains. Prior to Philips, he worked at Kreatech Diagnostics on the development of probes for drug targeting and microarray-based detection of DNA, RNA and proteins. In addition, he was a visiting scientist at the School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney.
Marc obtained his MSc and PhD in bio(in)organic chemistry at, respectively, the University of Groningen and the Leiden Institute of Chemistry, The Netherlands. He has published 39 peer-reviewed papers and is a co-inventor on 21 patents.
Seminars
- Breaking down rationale and mechanism for click-to-release chemistry to develop ADCs with reduced off-target toxicity
- Highlighting key toxicity and PK aspects from the TGW101 program to support the safety benefits of the Click-to-Release ADC approach
- Bringing learnings from TGW101 improved safety profile to ongoing ADC discovery across targets, protein formats and payloads to advance click-cleavable ADCs with mechanism-driven improved tolerability and therapeutic index
